Enzymatica reports Q3 2026 financial results and new market expansions
Net sales were SEK 14.6 million with a partnership in the MENA region for ColdZyme distribution. The company also secured additional loan facilities.
See the latest news and media coverage for Enzymatica. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of enzyme-based solutions against viruses, irritants, and microorganisms
enzymatica.comLast updated
In short: Enzymatica reported Q3 2026 results, expanded ColdZyme via MedonyX and STADA, and gained Truls Möregårdh as investor.
Net sales were SEK 14.6 million with a partnership in the MENA region for ColdZyme distribution. The company also secured additional loan facilities.
Net sales decreased to SEK 18.6 million while operating losses widened. The company announced a new Nordic marketing director and a partnership with Unibet Rose Rockets.
Net sales fell to SEK 7.1 million, with operating loss improved to SEK -12.6 million.
The company secured a strategic partnership with STADA for Germany and Austria. It also obtained an SEK 8 million loan facility from board members.
Enzymatica AB (publ) reported earnings results for the third quarter and nine months ended September 30, 2026. For the third quarter, the company reported sales...
The agreement marks an important breakthrough for Enzymatica and opens opportunities in one of Europe's largest self-care markets. Net sales for the quarter amounted to...
Enzymatica, which markets the cold spray Coldzyme, has signed a partnership agreement with Stada regarding launch and distribution of...
Net sales reached SEK 15,0 (12,6) million. The operating result totaled SEK -8,2 (-6,4) million. Earnings per share, basic and diluted, were SEK -0.03 (-0.04...
Track Enzymatica and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Discover what's making headlines across other trending companies.